PharmAla Biotech Logo 800 x 422.png
PharmAla Partners with Clariti Strategic Advisors™
November 08, 2023 08:55 ET | PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Biotech Logo 800 x 422.png
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
November 07, 2023 08:55 ET | PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
OptimiTM-03.jpg
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
November 07, 2023 07:30 ET | Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.
OptimiTM-03.jpg
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
November 02, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Logo Final.png
Lucy Scientific Discovery’s Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health
October 18, 2023 07:00 ET | Lucy Scientific Discovery Inc.
From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health ther
Sunstone Therapies logo.jpg
Sunstone Therapies Announces Expansion of Innovative Dyad Study
October 03, 2023 07:00 ET | Sunstone Therapies
Sunstone Therapies Announces Expansion of Innovative Dyad Study Expansion of Phase 2 pilot trial to assess MDMA-assisted therapy for adjustment disorder in dyads of patients with cancer and a...
PharmAla Biotech Logo 800 x 422.png
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
September 25, 2023 08:55 ET | PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty
OptimiTM-03.jpg
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
September 14, 2023 14:59 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
OptimiTM-03.jpg
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program
September 07, 2023 07:30 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly...
PharmAla Biotech Logo 800 x 422.png
PharmAla Begins Trading on OTCQB
September 06, 2023 08:55 ET | PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...